The United States FDA has approved the Abbott HeartMate 3 medical device. The Abbott HeartMate 3 is the only device to support as "bridge to transplant" therapy. This device simulates the beating of the heart (pulse) and helps the heart in pumping oxygen-rich blood to the body organs including to the heart until the patient receives a heart transplant or a total artificial heart.
The function of this device is safe and effective with fewer complications than the traditional left ventricular assist device (LVAD). The clinical trial of HeartMate 3 medical device was published in February 2017. The trial shows fewer problems and fewer strokes to the patient with the device compared with other models.
The life expectancy of a heart failure patient without the LVAD is 12 months or less. But, with the LVAD, 80 to 85 percent of heart failure patients are alive even after 12 months and 70 to 75 percent of heart failure patients survived even after 24 months. The longest survival with the LVAD was seven years.
Medtronic also makes the left-ventricular assist devices (LVAD) and it is a competitor to the HeartMate 3 medical device. Cost of an LVAD is around $80,000 and the hospitals are willing to pay for the LVAD.
LVAD: Left-ventricular assist device is an electromechanical device to help the heart failure patient in circulating oxygen-rich blood to body organs. The device can help partially or completely.
They are different from artificial hearts. The right ventricular assist device (RVAD) are the devices for the support of right ventricle of the heart. These devices are used as a bridge to transplantation and allow the body and the heart to rest, heal and help the heart to improve its function.
Abbott Laboratories: Abbott Laboratories is an Illinois, the United States-based multinational healthcare company. The company was founded in 1888 by Calvin Abbott and the company deals with diagnostics, branded generic pharmaceuticals and medical devices.
Abbott Laboratories products are being used worldwide by doctors, hospitals, laboratories and blood banks to diagnose and monitor the health of an individual.
The human body requires little salt (as salt contains sodium). The human body gets sodium from the food we eat. The World Health Organization (WHO) limits the salt consumption to five grams per day. Too much of salt consumption is bad for the health of an individual. The researchers are yet to find out the mechanism behind the increased health risks associated with the excess levels of sodium in the body.
A current study shows a twofold increased risk of heart failure with the increased consumption of salt. The study also shows a high quantity of salt consumption is associated with high blood pressure (hypertension) and the salt consumption is an independent risk factor for heart failure, stroke and coronary heart disease (CHD).
In the study, researchers used "24-hour sodium excretion" method to judge the salt consumption in 4,630 men and women participants, aged between 25 and 64 from the Finish data available at the National FINRISK Study and the North Karelia Salt Study. At the baseline, researchers have collected the health habits, blood pressure (BP), height, body mass index (BMI), 24-hour urine specimen and blood tests from the participants.
The researchers have equated to one gram of sodium consumption to 17.1 millimoles (mmol) of excreted sodium from the 24-hour urine specimen. The researchers followed the National Health Records of the participants for 12 years. They gathered new heart failure events and deaths related to heart failure from the Hospital Discharge Register, Causes-of-Death Register and the drug and treatment reimbursement records. They found 121 heart failure events.
The study shows that about two-times-higher risk of heart failure in people consuming more than 13.7 grams of salt compared to people consuming less than 6.8 grams of salt.
The risk of heart failure with the excess consumption of salt (or sodium) is independent of other health factors associated with hypertension (or high blood pressure. BP). The researchers accounted for other risk factors for heart diseases in the study.
The first author of the study was Professor Pekka Jousilahti, MD, Ph.D., Department of Chronic Disease Prevention, the National Institute for Health and Welfare, Helsinki, Finland. The study was presented in August 2017, to the European Society of Cardiology (ESC) Congress in Barcelona, Spain. Title of the article was "High salt intake associated with doubled risk of heart failure."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.